(V1543) |
Myofibroblasts as inflammatory supporter cells trigger cardiac inflammation in heart failure due to increased mechanical stretch |
|
D. Westermann, D. Lindner, H.-P. Schultheiss, C. Tschöpe (Berlin) |
(V1544) |
MiR-21 mediates interstitial fibrosis in cardiac allografts by supporting monocyte to fibroblast transition |
|
S. K. Gupta, J. Fiedler, C. Falk, S. Heymans, T. Thum (Hannover; Maastricht, NL) |
(V1545) |
The deficiency of PAR2 leads to an age dependent cardiac fibrosis and left ventricular dysfunction |
|
A. Weithäuser, R. Malz, K. Savvatis, H.-P. Schultheiss, U. Rauch-Kröhnert (Berlin) |
(V1546) |
The role of stabilin-1 as a marker for alternative macrophage activation in development of fibrosis in myocardium of dilatative cardiomyopathy patients with left ventricular assist device implantation |
|
K. Wassilew, E. Potapov, C. Schmuttermaier, A. Mickley, A. Gratchev, R. Hetzer, J. Kzhyshkowska (Berlin, Mannheim) |
(V1547) |
Inhibition of the Overactivated Cannabinoid-1 Receptor Signaling Attenuates Cardiac Dysfunction, Inflammation, and Fibrosis in Diabetic Cardiomyopathy |
|
S. Batkai, R. Mohanraj, P. Mukhopadhyay, B. Horvath, R. Cinar, G. Hasko, K. Mackie, L. Liaudet, P. Pacher (Hannover, Lausanne; Bethesda, Newark, Bloomington, US) |
(V1548) |
Cardiac-specific deletion of the CaMKII isoforms δ and γ protects against angiotensin-dependent perivascular fibrosis |
|
S. Schmidt, M. Kreußer, L. H. Lehmann, J. Krebs, H. A. Katus, J. Backs (Heidelberg) |